TxCell names François Meyer as chief executive

Prepares to take lead product candidates into clinical trials

TxCell, a French biotechnology company developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need, has appointed François Meyer as chief executive.

The company is preparing to further the development of its lead product candidate for the treatment of refractory Crohn’s disease patients into Phase IIb trials and move its second product candidate into a Phase I/II clinical trial for the treatment of refractory rheumatoid arthritis patients.

Meyer has more than 25 years of pharmaceutical and biotechnology experience. During the early part of his career, he held various executive positions in r&d at Ciba-Geigy Pharma, where he headed the Molecular Genetics department in the newly formed Biotechnology division and at Sandoz Pharma, where he led the Gene and Cell Therapy business.

After joining Rhone Poulenc Rorer in 1996, where he first headed r&d at Gencell, a biotechnology division of Rhone Poulenc Rorer, Meyer was promoted to head of Global Research in 1998 and became head of r&d at Aventis Pharma, France after the merger with Hoechst in 2000. Lately he was ceo of Centelion until 2006, a biopharmaceutical affiliate company of Aventis Pharma.

You may also like

Research & Development

TxCell names Lonza as its CAR-Treg cellular product manufacturer

Master Service Agreement signed between Lonza Pharma & Biotech and TxCell for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200)
Research & Development

TxCell Signs inlicensing agreement with Inserm Transfert for novel population of regulatory T cells

TxCell SA, a biotechnology company developing innovative, personalised cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, and Inserm Transfert, on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU, have announced the signature of an exclusive worldwide licensing agreement
Manufacturing

TxCell signs strategic agreement with MaSTherCell to manufacture cell therapy products

Company commits to an ambitious product development schedule with two discovery platforms
Manufacturing

TxCell to cut 26 jobs as it reviews its manufacturing strategy

Will focus on R&D and open a new laboratory close to its headquarters in Sophia Antipolis
Research & Development

TxCell raises around €8m in share placement

Will use proceeds to accelerate T-Cell developments and form partnerships with CMOs
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster
Subscribe now